Magenta Therapeutics (NASDAQ: MGTA)
Some price data may be temporarily unavailable.
Magenta Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Magenta Therapeutics Company Info
Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA.
News & Analysis
Big Pharma Is Going Holiday Shopping. Who's Next?
After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
Magenta Is Ready to Paint Your Portfolio Green
This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.
Why Shares of Magenta Therapeutics Are Plunging Today
The company announced the pricing of a public offering of common stock.
2 Small-Cap Biotechs That Soared Last Week
New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.
3 Stocks That Have More Than Tripled So Far in 2019
Can you guess what these high-flying stocks have in common?
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.